The FDA made a historic move on September 12, 2013 with their nod to approve Pertuzumab, a monoclonal antibody (mAb), as a pre-surgical treatment for patients with early-stage metastatic breast cancer. Pertuzumab is currently approved as a treatment for women with late-stage breast cancer, but it is administered after surgery has been completed. This new[…]
FDA Backs Novel First-Line Treatment Pertuzumab for Early Stage Breast Cancer
Chemotherapeutic / Anti-Neoplastic, Monoclonal Antibodies / mAb Tags: breast cancerDocetaxelHER2-positiveHerceptin Sep 18, 2013
New Phase III Trials to Begin for Trastuzumab in 2013
Chemotherapeutic / Anti-Neoplastic, Drug Research & Development API, Monoclonal Antibodies / mAb Tags: 180288-69-1AnthracyclineschemotherapyHER2-positiveHerceptinTrastuzumab Jan 14, 2013
Exemplary results in the 2012 Phase III trial coined EMILIA has led Roche Pharmaceuticals to initiate additional Phase III trials evaluating trastuzumab emtansine. The New Year brings registration trials for newly diagnosed as well as previously treated metastatic HER2-positive breast cancer patients. Trastuzumab will be evaluated in this 2013 study for three settings in earlier-stage[…]
Trastuzumab and Chemo Combo for Advanced Gastroesophageal Junction Cancer
Monoclonal Antibodies / mAb Tags: 180288-69-1chemotherapyHER2-positiveHerceptinTrastuzumab May 16, 2011
A study conducted by the Seoul National University College of Medicine, Seoul in South Korea found that the monoclonal antibody, Trastuzumab (Herceptin) used with chemotherapeutic drugs in the treatment of HER2-positive advanced gastroesophageal junction cancer showed a promising new treatment option for patients. HER2 protein is responsible for cell growth and division and the cell[…]